A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine

In conclusion, high-dose EPA has significantly reduced migraine frequency and severity, improved psychological symptoms and quality of life in EM patients, and shown no major adverse events, suggesting its potential as a prophylactic for EM.PMID:38499208 | DOI:10.1016/j.bbi.2024.03.019

Source: Brain, Behavior, and Immunity - March 18, 2024 Category: Neurology Authors: Hsueh-Fang Wang Wen-Chun Liu Halliru Zailani Cheng-Chia Yang Ting-Bin Chen Ching-Mao Chang I-Ju Tsai Chun-Pai Yang Kuan-Pin Su Source Type: research